Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH and Economou JS (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4: 17–25
Berd D, Maguire HC, Jr, McCue P and Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8: 1858–1867
Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK and Inglis SC (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet 347: 1523–1527
Brossart P, Goldrath AW, Butz EA, Martin S and Bevan MJ (1997) Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158: 3270–3276
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543
Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, Gentilini O and Braga M (1996) Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 104: 1–5
Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M and Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713–716
Harris JE, Ryan L, Hoover HC, Jr, Stuart RK, Oken MM, Benson AB, 3rd, Mansour E, Haller DG, Manola J and Hanna MG, Jr (2000) Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 18: 148–157
Hawkins RE, Winter G, Hamblin TJ, Stevenson FK and Russell SJ (1993) A genetic approach to idiotypic vaccination. J Immunother 14: 273–278
Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson L, Ouwehand W, Stevenson F, Hamblin T, Oscier D, Zhu D, King C, Kumar S, Thompsett A and Stevenson GT (1997) A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther 8: 1287–1299
Hsieh CL, Chen DS and Hwang LH (2000) Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther 11: 681–692
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG and Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52–58
Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F and Knuth A (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71: 142–147
Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA and Roberts BL (1999) Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163: 699–707
King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J and Stevenson FK (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [see comments]. Nat Med 4: 1281–1286
Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA and Ringert RH (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6: 332–336
Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H and Zinkernagel RM (2000) Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191: 795–804
Matzinger P (1994) Tolerance, danger and the extended family. Annu Rev Immunol 12: 991–1045
Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E and DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183: 1357–1365
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328–332
Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, Leiferman KM, Owens AH, Jr, Piantadosi S, Dranoff G, Mulligan RC, Pardoll DM and Marshall FF (1997) Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 57: 1537–1546
Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S and Hawkins RE (1995) Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 145: 211–228
Syrengelas AD, Chen TT and Levy R (1996) DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2: 1038–1041
Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD and Levy R (2001) Idiotype-encoding recombinant adenovirus provide protective immunity against murine B-cell lymphomas. Blood 97: 1370–1377
Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM and Melief CJ (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186: 695–704
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Armstrong, A., Dermime, S. Developing effective cancer vaccines: design and monitoring are critical. Br J Cancer 84, 1433–1436 (2001). https://doi.org/10.1054/bjoc.2001.1839
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1839